The price target is the mean estimate from the 10 research brokerages that recently issued reports on the firm. On a scale of one to five, with one representing a strong buy and five representing a strong sell, the equity is ranked 1.67 based on broker recommendations. In the long term, analysts have estimated a consensus mean earnings per share of $1.09 for the current year, according to the report.
More articles on devices:
Symmetry Medical to close Indiana orthopedic implant facility
NuVasive CEO resigns after compliance investigation — 5 things to know
Orthofix stock gains big — 14%: 5 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
